Amwell boosted its 2026 guidance after a strong third quarter and said it is positioning its unified virtual care platform as infrastructure for AI-enabled care as health plans and employers adopt more tools.
Waystar again topped analyst estimates in the third quarter, citing bigger health system wins and a growing AI pipeline as it sells more of its platform to new and existing clients.
Why it matters: Extends hospital operations AI from capacity planning to real-time room monitoring via acquisition.
LeanTaaS is expanding iQueue beyond hospital capacity management by acquiring LookDeep Health, adding computer vision that monitors patient rooms and turns real-time signals into prioritized actions for care teams.
Midstream Health raised a $20 million series A for its AI financial platform, which it says helps hospitals recover lost margin by finding money embedded in contracts and transactions.
A Distilled Post piece examines the fallout for British doctors whose AI documentation scribe lost its founders, raising questions about reliability and support.
Tech.eu reports SFC Capital is backing Nayara's AI platform for patient care, following the UK healthtech's pre-seed round.
Medical AI company Lunit plans to issue USD 36 million in convertible bonds to refinance higher-rate debt, Wowtale reports.
MindWalk (NASDAQ:HYFT) signed a multi-year agreement with Teva Australia covering its AI drug discovery platform, Kalkine reports.
Why it matters: Clinical data from an AI-driven drug pipeline is a key test of the discovery model.
Recursion Pharmaceuticals released Phase 2 REC-4881 trial data and appointed a new board chair alongside Q3 earnings and clinical updates, prompting investor analysis.
Algorae expanded its pharmaceutical portfolio and validated its AI drug discovery platform, according to TipRanks.
Why it matters: A $50B valuation would make it one of the most valuable AI drug discovery companies.
Alphabet's Isomorphic Labs is reportedly in talks to raise about $5B at a roughly $50B valuation, per Bloomberg, as the AI drug discovery lab scales up.
Stocks Down Under examines why Nvidia invested in Recursion Pharmaceuticals and whether its AI platform could change drug discovery.
Tsinghua-backed Tairex raised roughly $15M in an angel round to build an AI hospital system, according to Dealroom.
Why it matters: Consolidates AI digital pathology under a major lab instruments buyer.
Agilent completed its acquisition of Proscia for up to $270M, expanding AI-powered digital pathology capabilities, citybiz reports.
OneMedNet received a mid six-figure re-order from a foundation model company developing radiology models, GlobeNewswire reports.
nPhase raked in $30 million to expand its AI-native clinical data platform.